Teknova Q2 revenue $11.5M (+26% seq, -1% YoY); cuts 2023 revenue guidance to $37-40M

Alpha Teknova, Inc.

2023-Q2 EPS reported -$0.57 revenue$20,648,000

Q2 revenue $11.5M, up 26% sequentially but down 1% YoY; net loss $7.2M ($0.25/share).
Clinical Solutions revenue grew 24% YoY to $3.7M; Lab Essentials fell 10% to $7.6M.
Company reduces 2023 revenue guidance to $37-40M from prior; maintains free cash outflow ~$30M.
Received certification for new GMP production facility, expanding capacity to $200M.
Adjusted EBITDA improved to -$2.3M from -$4.9M; non-cash impairment charge of $2.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alpha Teknova, Inc. reported the second quarter ended June 30, 2023 results: revenue $11.5 million, EPS negative $0.25 per diluted share. Guidance lowered.

Period: the second quarter ended June 30, 2023
Revenue: $11.5 million
EPS: negative $0.25 per diluted share
Guidance: lowered
Result: reported results

Exact text from the filing

to be furnished under Item 2.02 and --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Teknova Reports Second Quarter 2023 Financial Results Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million,

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alpha Teknova, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.